Liensinine and Nuciferine, Bioactive Components of Nelumbo nucifera, Inhibit the Growth of Breast Cancer Cells and Breast Cancer-Associated Bone Loss
Liensinine prevented breast cancer-induced bone loss in mice. MDA-MB-231 cells were injected into the tibiae of nude mice (). Liensinine was administered orally five times per week and zoledronic acid (0.1 mg/kg) was injected subcutaneously 3 times per week for 5 weeks. (a) Experimental design. (b) X-ray images were taken on week 5. (c) Serial sections of mouse tibiae and femora were stained with hematoxylin-eosin. Tm: tumor mass, BM: bone marrow, Fm: femur, and Tb: tibia. (d) Bone morphometric parameters, BV/TV (%), Tb.Th (mm), Tb.N (1/mm), Tb.Sp (mm), and SMI, were analyzed with micro-CT. (e) Serum bone resorption markers, TRAP5b and CTX, were analyzed using the respective kits. Data are expressed as the means ± SE. and versus control mice without MDA-MB-231 cells; and versus cancer cell-inoculated mice with vehicle (PBS containing 1% DMSO) alone.